Collegium Pharmaceutical (COLL) reported $188 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 29.4%. EPS of $1.68 for the same period compares to $1.62 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $180.38 million, representing a surprise of +4.23%. The company delivered an EPS surprise of +3.7%, with the consensus EPS estimate being $1.62.While investors closely watch year-over-year changes in headline numbers -- revenue and earnin ...

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.68 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.70%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $1.43 per share when it actually produced earnings of $1.49, delivering a surprise of +4.2%.Over the ...

Collegium Pharmaceutical (COLL) Q2 2025 Earnings Call August 07, 2025 08:00 AM ET Speaker0At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I'll now turn the conference over to Ian Karp, Head of Investor Relations at Collegium.Thank you. You may now begin your presentation.Speaker1Great. Thanks and welcome to Collegium Pharmaceutical's second quarter twenty twenty five earnings conferenc ...

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this pre ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR (Exact name of registrant as specified in its charter) Virginia (State or other jurisdiction of incorporation or organization) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...

– Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $745 to $760 Million and Adjusted EBITDA Guidance in the Range of $440 to $455 Million ...

股价表现与目标价分析 - Collegium Pharmaceutical(COLL)最新收盘价为32 11美元 过去四周涨幅达7 4% 华尔街分析师给出的平均目标价43美元意味着33 9%上行空间 [1] - 五个短期目标价区间为37至50美元 标准差5 1美元 最低目标价隐含15 2%涨幅 最高目标价隐含55 7%涨幅 标准差反映分析师预测分歧程度 [2] - 分析师目标价共识虽受投资者关注 但单纯依赖该指标可能误导投资决策 需结合其他因素 [3] 盈利预测修正 - 分析师普遍上调COLL盈利预测 显示对公司前景的乐观情绪 盈利预测修正趋势与股价上涨存在实证相关性 [4] - 过去30天Zacks共识预期上调0 5% 仅见正面修正未见负面调整 [12] - 公司当前获Zacks Rank 2(买入)评级 位列4000多只股票前20% 该评级基于盈利预测相关四项因素 具有较高参考价值 [13] 目标价可靠性研究 - 全球多所大学研究表明 分析师目标价常误导投资者 实证显示其预测准确度有限 无论分析师共识程度如何 [7] - 华尔街分析师可能因商业利益设置过高目标价 尤其涉及投行现有客户或潜在合作企业时 [8] - 低标准差目标价集群反映分析师对股价方向判断一致 可作为研究起点 但不应视为绝对依据 [9] 综合投资建议 - 投资者不应完全忽视目标价 但需保持审慎态度 避免仅凭该指标决策 [10] - 尽管目标价共识未必可靠 但其指示的股价方向仍具参考意义 需结合盈利预测修正等基本面因素 [14]

文章核心观点 - 公司将于2025年8月7日开市前公布2025年第二季度财报，并于上午8点举办电话会议和网络直播 [1] 会议信息 - 可拨打(877) 407 - 8037（美国）或(201) 689 - 8037（国际）参加电话会议，并提及“Collegium Pharmaceutical Q2 2025 Earnings Call” [2] - 可从公司网站投资者板块获取音频网络直播，活动约两小时后可在网站观看重播 [2] 公司概况 - 致力于改善重症患者生活，拥有领先的疼痛管理药物组合，近期收购用于治疗多动症的Jornay PM，进军神经精神科领域 [3] - 战略包括扩大商业产品组合，以Jornay PM为主要增长驱动力，有纪律地配置资本 [3] - 总部位于马萨诸塞州斯托顿，更多信息可访问公司网站www.collegiumpharma.com [3] 投资者联系方式 - 投资者关系负责人Ian Karp，邮箱ir@collegiumpharma.com [4] - 投资者关系总监Danielle Jesse，邮箱ir@collegiumpharma.com [4]

股票回购 - 股票回购是提升股价的有效工具 尤其在公司基本面稳健时 通过减少流通股提升每股收益并向市场传递信心 [1] - 多家公司在6月至7月初宣布大规模回购计划 结合强劲资产负债表和战略性资本回报 [1] Collegium制药 - 专注于疼痛管理的小型药企 2025年关键亮点包括收入增长 管线进展 盈利能力提升及强劲股东回报 [2] - Q1流通股同比减少20% 新授权1 5亿美元回购计划替代现有方案 [3] - Q1财报显示现金增加 无形资产减少 总负债持平 长期债务权益比约3倍 财务健康 [4] Enovix - 7月初启动6000万美元两年回购计划 金额超过2025年收入预期 [6] - 制造能力提升 新产品及终端市场需求推动可持续超高速增长 2026年收入增长预期超300% [7] - Q1现金2 48亿美元与总负债相当 杠杆率低现金流改善 回购金额占市值2 3% [7][8] Thor工业 - 重新授权4亿美元回购计划 占7月初市值8%以上 将显著提升股东价值 [11][12] - 后疫情期行业正常化后恢复增长 利润率扩大支撑现金流 股息率约2 2% [12][13] Darden餐饮 - FQ4财报显示增长 利润率改善 新授权10亿美元回购计划 占发行量3 8% [16] - 出售表现不佳的Bahama Breeze业务 聚焦核心业务并获取现金注入 [17][18] Fifth Third Bancorp - 重新授权1亿股无期限回购计划 此前剩余118万股 结合3 45%股息率及中个位数年增长 [22] - 19名分析师追踪中维持"适度买入"评级 共识目标价隐含10%上行空间 [23]

政策创新与监管服务 - 乐城先行区通过创新监管服务机制快速引进"零关税"进口药械，实现政策出台即见效 [1][2] - 多部门联动打造特许医疗综合追溯管理平台，整合优惠政策申请事项，实现一次操作满足多部门需求 [3][4] - 平台实现与海关系统无缝对接，申报信息实时传递，操作便捷高效 [4] 政策落地成效 - 全球首发智能人工耳蜗植入系统Nexa通过"零关税"政策引进，首批购买50套，货值约1500万元，减免税额超百万元 [2] - 截至2024年6月30日，14家医疗机构通过享惠主体资格认定，累计引进58批次进口药械，免税总货值超1.3亿元，减免税款累计超1800万元 [4] - 树兰(博鳌)医院已完成约50台Nexa智能人工耳蜗植入手术 [2] 监管技术与流程优化 - 开发"政策准入—通关申报—临床使用"全链条区块链存证追溯系统，实现产品引进到患者使用的全流程追踪 [6] - 为医疗机构整理信息填写指南，覆盖上百条海关报关信息需求，简化填写流程 [6] - 系统优化后实现产品信息同步导入，医疗机构无需重复手动输入 [6] 未来发展方向 - 将持续优化平台及机制，扩大园区享惠主体和药械品种，进一步释放政策红利 [7] - 系统可自动识别使用异常并推送警报，确保进口药械真正惠及患者 [7]